These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 14670691)

  • 1. A method for evaluating drug effects on intermittent claudication using a treadmill in rats with unilateral hindlimb artery occlusion.
    Orito K; Kishi M; Fujiki H; Nakazawa T; Imaizumi T; Kimura Y; Mori T; Kambe T
    J Pharmacol Toxicol Methods; 2004; 49(1):25-9. PubMed ID: 14670691
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combination of Cilostazol and L-Carnitine Improves Walking Performance in Peripheral Arterial Disease Model Rats.
    Shiga T; Sahara H; Orito K
    Pharmacology; 2015; 96(5-6):210-6. PubMed ID: 26329263
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of cilostazol and pentoxifylline on gait biomechanics in rats with ischemic left hindlimb.
    Bredarioli M; Dalio MB; Joviliano EE; do Prado WA; Piccinato CE
    J Vasc Surg; 2012 Aug; 56(2):476-81. PubMed ID: 22503175
    [TBL] [Abstract][Full Text] [Related]  

  • 4. NT-702 (parogrelil hydrochloride, NM-702), a novel and potent phosphodiesterase inhibitor, improves reduced walking distance and lowered hindlimb plantar surface temperature in a rat experimental intermittent claudication model.
    Ishiwata N; Noguchi K; Kawanishi M; Asakura Y; Hori M; Mitani A; Ito Y; Takahashi K; Nishiyama H; Shudo N; Takahashi S; Takahashi K; Tsuruzoe N; Nakaike S
    Life Sci; 2007 Sep; 81(12):970-8. PubMed ID: 17850826
    [TBL] [Abstract][Full Text] [Related]  

  • 5. L-Carnitine plus cilostazol versus cilostazol alone for the treatment of claudication in patients with peripheral artery disease: a multicenter, randomized, double-blind, placebo-controlled trial.
    Goldenberg NA; Krantz MJ; Hiatt WR
    Vasc Med; 2012 Jun; 17(3):145-54. PubMed ID: 22615190
    [TBL] [Abstract][Full Text] [Related]  

  • 6. K-134, a phosphodiesterase 3 inhibitor, improves gait disturbance and hindlimb blood flow impairment in rat peripheral artery disease models.
    Sasaki Y; Suzuki H; Itoh S; Yoshida H; Kondo S; Inoue K; Tanabe S
    Eur J Pharmacol; 2012 Aug; 689(1-3):132-8. PubMed ID: 22659587
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prostaglandin E1 -containing nanoparticles improve walking activity in an experimental rat model of intermittent claudication.
    Ishihara T; Yamashita Y; Takasaki N; Yamamoto S; Hayashi E; Tahara K; Takenaga M; Yamakawa N; Ishihara T; Kasahara T; Mizushima T
    J Pharm Pharmacol; 2013 Aug; 65(8):1187-94. PubMed ID: 23837586
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of cilostazol on resting ankle pressures and exercise-induced ischemia in patients with intermittent claudication.
    Mohler ER; Beebe HG; Salles-Cuhna S; Zimet R; Zhang P; Heckman J; Forbes WP
    Vasc Med; 2001; 6(3):151-6. PubMed ID: 11789969
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cilostazol promotes angiogenesis after peripheral ischemia through a VEGF-dependent mechanism.
    Biscetti F; Pecorini G; Straface G; Arena V; Stigliano E; Rutella S; Locatelli F; Angelini F; Ghirlanda G; Flex A
    Int J Cardiol; 2013 Aug; 167(3):910-6. PubMed ID: 22473072
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of withdrawal of drugs treating intermittent claudication.
    Dawson DL; DeMaioribus CA; Hagino RT; Light JT; Bradley DV; Britt KE; Charles BE
    Am J Surg; 1999 Aug; 178(2):141-6. PubMed ID: 10487267
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of cilostazol in patients with intermittent claudication: a randomized, double-blind, placebo-controlled study.
    Strandness DE; Dalman RL; Panian S; Rendell MS; Comp PC; Zhang P; Forbes WP
    Vasc Endovascular Surg; 2002; 36(2):83-91. PubMed ID: 11951094
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hindlimb claudication reflects impaired nitric oxide-dependent revascularization after ischemia.
    Luque Contreras D; Jiménez Estrada I; Martínez Fong D; Segura B; Guadarrama JC; Paniagua Sierra R; Vargas Robles H; Rios A; Escalante B
    Vascul Pharmacol; 2007 Jan; 46(1):10-5. PubMed ID: 17011243
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phosphodiesterase 3 inhibitor, K-134, improves hindlimb skeletal muscle circulation in rat models of peripheral arterial disease.
    Yoshida H; Itoh S; Hara T; Sasaki Y; Kondo S; Nakagawa T; Asanuma A; Tanabe S
    Atherosclerosis; 2012 Mar; 221(1):84-90. PubMed ID: 22269153
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase II dose-ranging study of the phosphodiesterase inhibitor K-134 in patients with peripheral artery disease and claudication.
    Brass EP; Cooper LT; Morgan RE; Hiatt WR
    J Vasc Surg; 2012 Feb; 55(2):381-389.e1. PubMed ID: 22119244
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effects of cilostazol on exercise-induced ischaemia-reperfusion injury in patients with peripheral arterial disease.
    O'Donnell ME; Badger SA; Sharif MA; Makar RR; McEneny J; Young IS; Lee B; Soong CV
    Eur J Vasc Endovasc Surg; 2009 Mar; 37(3):326-35. PubMed ID: 19112032
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of cilostazol, a novel phosphodiesterase inhibitor in patients with intermittent claudication.
    Samra SS; Bajaj P; Vijayaraghavan KS; Potdar NP; Vyas D; Devani RG; Ballary C; Desai A
    J Indian Med Assoc; 2003 Sep; 101(9):561-2, 564. PubMed ID: 15168999
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Cilostazol is effective and safe option for the treatment of intermittent claudication. Results of the NOCLAUD study].
    Farkas K; Járai Z; Kolossváry E
    Orv Hetil; 2017 Jan; 158(4):123-128. PubMed ID: 28116935
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A functional murine model of hindlimb demand ischemia.
    Peck MA; Crawford RS; Abularrage CJ; Patel VI; Conrad MF; Yoo JH; Watkins MT; Albadawi H
    Ann Vasc Surg; 2010 May; 24(4):532-7. PubMed ID: 20363101
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Silencing of int6 gene restores function of the ischaemic hindlimb in a rat model of peripheral arterial disease.
    Okamoto N; Tanaka A; Jung K; Karasawa K; Orito K; Matsuda A; Amagai Y; Oida K; Ohmori K; Matsuda H
    Cardiovasc Res; 2011 Nov; 92(2):209-17. PubMed ID: 21771896
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of cilostazol after endovascular therapy for femoropopliteal artery disease in patients with intermittent claudication.
    Soga Y; Yokoi H; Kawasaki T; Nakashima H; Tsurugida M; Hikichi Y; Nobuyoshi M
    J Am Coll Cardiol; 2009 Jan; 53(1):48-53. PubMed ID: 19118724
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.